PVLA · Palvella Therapeutics, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.35M | — | — | $42.81M | $25.9M | $31.42M | $29.32M | $46.28M | $29.1M | $25.28M | $5.83M | $2.93M | $5.37M | $12.43M | |
| $4.19M | $2.59M | $642K | — | — | — | — | — | — | — | — | — | — | — | |
| $35.46M | $22.84M | $8.15M | $8.79M | $52.98M | $66.66M | $46.53M | $55M | $41.49M | $22.29M | $19.7M | $8.24M | $5.6M | $9.41M | |
| $22.29M | $15.76M | $5.94M | $3.08M | $16.39M | $16.59M | $16.71M | $18.44M | $18.44M | $17.58M | $8.89M | $8.37M | $6.96M | $2.46M | |
| -$228K | — | — | $1.9M | $2.77M | $2.46M | — | — | — | — | — | — | — | — | |
| $57.74M | $38.6M | $14.1M | $11.87M | $69.38M | $83.25M | $63.24M | $73.44M | $59.93M | $39.87M | $28.59M | $16.61M | $12.56M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $12.56M | $11.87M | |
| -$57.74M | -$38.6M | -$14.1M | -$11.87M | -$43.47M | -$51.83M | -$33.92M | -$27.16M | -$30.83M | -$14.59M | -$22.76M | -$13.68M | -$7.2M | $553.83K | |
| — | — | — | -27.72% | -167.84% | -164.97% | -115.68% | -58.68% | -105.94% | -57.74% | -390.31% | -466.62% | -134.17% | 4.46% | |
| $3.43M | — | — | -$9.97M | -$40.7M | -$49.37M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $2.65M | $493.94K | |
| -$98K | $727K | -$131K | $712K | $1.3M | $2.4M | -$3.66M | -$26K | $1.8M | -$2.1M | $120K | $10.91K | -$2.65M | -$487.63K | |
| -$61.7M | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M | -$37.07M | -$25.47M | -$27.07M | -$16.54M | -$22.64M | -$13.85M | -$9.85M | $66.2K | |
| $0 | $0 | $0 | $0 | $0 | $0 | $164K | $0 | -$312K | $1.1M | $162K | $203.87K | -$18 | — | |
| -$61.7M | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M | -$37.23M | -$25.47M | -$26.75M | -$17.65M | -$22.8M | -$14.06M | -$9.85M | $66.2K | |
| — | — | — | 43.66% | -128.47% | -145.58% | -126.97% | -55.03% | -91.93% | -69.82% | -391% | -479.5% | -183.59% | 0.53% | |
| -$32.37M | — | -$17.43M | $17.92M | — | — | -$37.23M | -$28.3M | -$26.75M | — | — | — | — | — | |
| -$61.5M | -$41.64M | -$17.43M | $17.92M | -$34.36M | -$44.61M | -$35.53M | -$24.48M | -$25.04M | -$20.84M | -$23.03M | -$14.49M | -$9.74M | $89.31K | |
| USD/shares | -$4.83 | -$3.71 | -$7.83 | $2.19 | -$36.00 | -$56.80 | -$54.40 | — | — | — | — | — | — | — |
| USD/shares | -$4.83 | -$3.71 | -$7.83 | $2.17 | — | -$56.80 | -$54.40 | — | — | — | — | — | — | — |
| shares | — | 11.25M | 2.23M | 1.77M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 173.4K | 147.86K |
| shares | — | 11.25M | 2.23M | 1.79M | — | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 173.4K | 147.86K |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 256 similar-size Biotechnology companies (of 537 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2019 |
|---|---|
| Customer Revenue | $32,065,000 |
| Collaboration Revenue | $14,214,000 |